Pozitivf Fertility is excited to announce the launch of our Preimplantation Genetic Testing for Monogenic diseases (PGT-M), a transformative approach that allows prospective parents to address genetic concerns before pregnancy. By identifying and selecting embryos free of specific genetic conditions, PGT-M offers a proactive path to a healthier family legacy.  

Our program is designed with precision and care, priced at $25,995, significantly below the national average of $40,000. This initiative includes a detailed genetic consultation, development of a personalized genetic probe, comprehensive egg retrieval, and testing of up to six embryos for both specific genetic diseases and chromosomal abnormalities. 

The inclusion of PGT-A testing complements the PGT-M process by examining embryos for broader chromosomal health, thereby enhancing implantation success rates and reducing the risk of miscarriage. This dual approach ensures a thorough assessment, maximizing the chances of achieving a healthy pregnancy. 

Moreover, the process encompasses ICSI, embryo transfer, and one year of embryo storage, providing couples flexibility and reassurance as they plan their future. Our mission is to make advanced reproductive technologies accessible, giving every family the best start possible. 

With this new service, we invite OBGYNs to refer patients who may benefit from enhanced genetic insights, particularly those with a known risk of inheritable diseases. Together, we can guide them towards realizing their dreams of parenthood, supported by the most comprehensive care available. 

Summary 

Pozitivf Fertility introduces affordable PGT-M cycles to identify embryos free from specific genetic diseases, offering a proactive approach to family planning. This comprehensive service includes genetic counseling, embryo testing, and storage, providing a pathway to healthier pregnancies for those with inheritable condition concerns.